Diego Salas‐Benito

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Marcela Valderrama Maus · 3 shared papers, 2024–2026 · strength 0.61
   • Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
   • Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
   • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
2. Giulia Escobar · 2 shared papers, 2025–2026 · strength 0.47
   • Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
   • Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
3. Sangwoo Park · 2 shared papers, 2025–2026 · strength 0.47
   • Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
   • Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
4. Alexander Armstrong · 1 shared paper, 2026 · strength 0.25
   • Paper Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Canc… DOI 10.1158/1078-0432.ccr-25-2907↗
5. Eli P. Darnell · 1 shared paper, 2025 · strength 0.22
   • Paper Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. DOI 10.1038/s41467-025-66102-2↗
6. Mariano Ponz‐Sarvisé · 1 shared paper, 2019 · strength 0.16
   • Paper Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack. DOI 10.1158/1078-0432.ccr-19-1753↗
7. David Tsai Ting · 1 shared paper, 2024 · strength 0.14
   • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
8. Marc Wehrli · 1 shared paper, 2024 · strength 0.14
   • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
9. Samantha R. Guinn · 1 shared paper, 2024 · strength 0.14
   • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
10. Genevieve Marie Boland · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
11. Richard Andrew Burkhart · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
12. Elizabeth M. Jaffee · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
13. Andrew Scott Liss · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
14. Lei Zheng · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
15. Jacquelyn W. Zimmerman · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.